Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
366 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,281 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC |
| unknown |
| Phase 1 / Phase 2 |
| 65 |
| Chinese PLA General HospitalOTHER |
| 1 |
| Apr 14, 2022 |
| clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03937895 | Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 40 | SMT bio Co., Ltd.INDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02591030 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours(AMEBICA) | completed | Phase 2 / Phase 3 | 191 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | terminated | Phase 2 | 1 | American University of Beirut Medical CenterOTHER | 3 | Feb 23, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | terminated | Phase 2 | 4 | Aiwu Ruth He, MDOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT03111732 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | completed | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02115542 | Single Agent Regorafenib in Refractory Advanced Biliary Cancers | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT03603834 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | unknown | Phase 2 | 25 | Khon Kaen UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT02631590 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT03093870 | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer(TreeTopp) | completed | Phase 2 / Phase 3 | 151 | ASLAN PharmaceuticalsOTHER | 11 | Aug 3, 2021 | clinicaltrials |
| NCT04961788 | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03951597 | Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT04656249 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer(LENABC) | completed | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04642664 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer(ACABC) | completed | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT03778593 | FOLFIRINOX for 2nd-line Treatment of BTC | completed | Phase 2 | 34 | Dong-A University HospitalOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04186156 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Karus Therapeutics LimitedINDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT03830606 | The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | completed | Phase 2 | 54 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | terminated | Phase 1 / Phase 2 | 204 | ASLAN PharmaceuticalsOTHER | 3 | Jan 14, 2021 | clinicaltrials |
| NCT03613168 | Trastuzumab in HER2-positive Biliary Tract Cancer(BILHER) | completed | Phase 2 | 4 | Changhoon YooOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT02579616 | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy | completed | Phase 2 | 29 | Eisai Co., Ltd.INDUSTRY | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03231176 | Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer | completed | Phase 2 | 62 | ASLAN PharmaceuticalsOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | completed | Phase 1 / Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01247337 | Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma | completed | Phase 2 | 56 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02428855 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2022source: clinicaltrials